The study consists of an open-label AXS-14 treatment period followed by a randomised, double-blind treatment period.

Axsome Therapeutics AXSM announced the initiation of the phase III study called FORWARD with the dosing of the first patient, ...

SOLON, Ohio--(BUSINESS WIRE)--Pioneering the frontier of super-pulsed laser technology, Multi Radiance Medical highlights the impact of FibroLux Therapeutic Laser, one of the first and only ...

AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor being developed for the management of fibromyalgia. Esreboxetine is the SS-enantiomer of racemic reboxetine.

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations ...

CHATHAM, NEW JERSEY / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp.

In patients with fibromyalgia, a 24-week treatment with a 50-mg/d dose of plant-derived cannabidiol did not outperform placebo in terms of pain relief or health-related quality of life. The only ...

UCSD and the Department of Veterans Affairs Collaboration CARLSBAD, CA, UNITED STATES, December 31, 2025 /EINPresswire.com/ — AVACEN Medical announced today that Dr. Francisco Cidral, ND, PhD’s ...

“TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Participants With Fibromyalgia” “Sublingual Cyclobenzaprine (TNX-102 SL) for Fibromyalgia ...

“This is the primary reason people with fibromyalgia search for a compassionate provider,” says Kevin V. Hackshaw, MD, a board-certified rheumatologist who specializes in fibromyalgia at UT Health ...

Fibromyalgia causes severe pain throughout the body. But scientists do not know the precise mechanisms that create this suffering. The pain usually develops gradually but can also seem to come out of ...